Mesenchymal Stromal Cell Secretome for Severe COVID-19 Infections: Premises for the Therapeutic Use

From the end of 2019, the world population has been faced the spread of the novel coronavirus SARS-CoV-2 responsible for COVID-19 infection. In approximately 14% of the patients affected by the novel coronavirus, the infection progresses with the development of pneumonia that requires mechanical ven...

Descripción completa

Detalles Bibliográficos
Autores principales: Bari, Elia, Ferrarotti, Ilaria, Saracino, Laura, Perteghella, Sara, Torre, Maria Luisa, Corsico, Angelo Guido
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Perspective
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7226831/
https://www.ncbi.nlm.nih.gov/pubmed/32283815
http://dx.doi.org/10.3390/cells9040924
Descripción
Sumario:From the end of 2019, the world population has been faced the spread of the novel coronavirus SARS-CoV-2 responsible for COVID-19 infection. In approximately 14% of the patients affected by the novel coronavirus, the infection progresses with the development of pneumonia that requires mechanical ventilation. At the moment, there is no specific antiviral treatment recommended for the COVID-19 pandemic and the therapeutic strategies to deal with the infection are only supportive. In our opinion, mesenchymal stem cell secretome could offer a new therapeutic approach in treating COVID-19 pneumonia, due to the broad pharmacological effects it shows, including anti-inflammatory, immunomodulatory, regenerative, pro-angiogenic and anti-fibrotic properties.

Ejemplares similares